Marker Therapeutics Inc (MRKR)

[rfj1862]

According to this post, the data will be released during ASCO whether their presentation is accepted or not. A follow—up would help.

I just called and spoke to someone in IR and asked if the abstract had been accepted. He said there's currently an embargo on releasing that information. He indicated that a PR would be likely for an acceptance, but not likely for a rejection. He couldn't say when it would be announced. I asked if we should be optimistic and he said based on their history of having abstracts accepted, he was optimistic that it would be accepted. He said regardless of ASCO's decision, the data would be released sometime during ASCO. I also asked if Marker is currently seeking from the FDA "Breakthrough Therapy Designation" for any of the indications that are being treated. He said he didn't know, but said he would find out.

Depending on who this person talked to--someone at the company or their outsourced investor relations, the confidence that you can have in their answer that "regardless of ASCO's decision, the data would be released sometime during ASCO" could be high to low.

Their IR company, SolesburyTrout, is really a seriously bottom of the barrel operation so if this person was talking to one of them you really can't have any confidence whatsoever in the answers you are given.

The company desperately needs to engage a real medical communications agency.